Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD

Richard E. Pratley MD

Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute, Orlando, Florida; Medical Director, AdventHealth Diabetes Institute, Orlando, Florida; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Dr. Richard Pratley, an internationally recognized expert in diabetes, is Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute and Medical Director of the AdventHealth Diabetes Institute in Orlando, as well as Adjunct Professor of Medicine, Johns Hopkins University School of Medicine.

Dr. Pratley is a principal investigator for both NIH- and pharmaceutical company–sponsored trials in diabetes and obesity. His current research interests include the prevention of diabetes, improving the care of older individuals with diabetes, developing new drugs to treat and prevent diabetes and its complications, understanding the role of the fat cell in increasing the risk for diabetes and heart disease, and investigating extracellular vesicles in inter-cellular and inter-organ cross-talk. He presents his research regularly at national and international meetings and has written over 400 peer-reviewed articles. He is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has served on the editorial boards of a number of high-impact journals, including Diabetes Care, The Lancet Diabetes &Endocrinology, The Journal of Clinical Endocrinology and Metabolism, and the Journal of Diabetes and Its Complications.

Disclosures

  • Speaker fees: Eli Lilly; Novo Nordisk
  • Consulting fees: AbbVie; AstraZeneca; Bayer AG; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Corcept Therapeutics; Eli Lilly; Endogenex; Gasherbrum Bio; Genprex; Getz Pharma; Hanmi Pharmaceutical Co; Intas Pharmaceuticals; Lexicon Pharmaceuticals; Lilly USA; Novo Nordisk; Pfizer; Regeneron; Rivus Pharmaceuticals, Scholar Rock; Sun Pharmaceutical Industries
  • Grants: Biomea Fusion; Carmot Therapeutics; Dompé; Endogenex; Fractyl Health; Eli Lilly; Novo Nordisk; Sanofi
  • Stock options: Altanine, Inc
  •  

Recent Contributions to PracticeUpdate:

  1. Use and Discontinuation of Insulin Treatment Among Older Adults With Type 2 Diabetes
  2. Oral Semaglutide vs Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin
  3. Oral Semaglutide Is Safe and Effective Added to Insulin ± Metformin in Patients With T2D
  4. The Association Between Polypharmacy and Adverse Health Consequences in Elderly Patients With Type 2 Diabetes
  5. Efficacy and Safety of Oral Semaglutide With Flexible Dose Adjustment vs Sitagliptin in Type 2 Diabetes
  6. DPP-4 Inhibitors and Risk of IBD Among Patients With Type 2 Diabetes
  7. ADA Scientific Sessions 2019: Recommendations From Dr. Richard Pratley
  8. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
  9. 2018 Top Stories in Diabetes: The ASCEND Study
  10. Type 2 Diabetes and Fatty Liver/Non-alcoholic Steatohepatitis

Most Read This Week

Recently Updated